1.31 Ketogenic Diet, COMET-1 and COMET-2, the Health Insurance Marketplace with Dr. Jane Zhu

Plenary Session

English - December 27, 2018 00:45 - 1 hour - 81.6 MB - ★★★★★ - 722 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 1.30 BONUS! Clinical Trial Endpoints, Drug Approval, Incentives in Oncology

Next Episode: 1.32 Rating Metrics, Conflict of Interest in the News, & Radiation Oncology with Dr. Brian Kavanagh

We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the health insurance marketplace with Dr. Jane Zhu of OHSU, an expert in the Affordable Care Act.

Keto diet + PI3 kinase: https://www.nytimes.com/2018/12/05/magazine/its-time-to-study-whether-eating-particular-diets-can-help-heal-us.html
COMET-1: http://doi.org/10.1200/jco.2015.65.5597
COMET-2: https://doi.org/10.1016/j.eururo.2018.11.033

Back us on Patreon! https://www.patreon.com/plenarysession